Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

作者：Kanakry Christopher G^*; de Lima Marcos J; Luznik Leo

来源：Seminars in Hematology, 2015, 52(3): 232-242.

DOI：10.1053/j.seminhematol.2015.03.005

Allogeneic hematopoietic cell transplantation (alloHCT) provides a potentially curative therapy for patients with high-risk or chemorefractory acute myeloid leukemia (AML). Historically, the applicability of alloHCT has been limited as only 30%-35% of patients have human leukocyte antigen (HLA)matched siblings and outcomes using other donor types have been markedly inferior due to excess toxicity, graft failure, graft-versus-host disease (GVHD), and consequently non-relapse mortality. Advances in HLA typing, GVHD prophylactic approaches, and other transplantation techniques have successfully addressed these historical challenges. Herein, we review recent alloHCT studies using volunteer unrelated donors, umbilical cord blood units, or HLA-haploidentical donors, specifically focusing on studies that compared outcomes between donor sources. Although none are randomized and most are retrospective, these analyses suggest that current outcomes for AML patients using most alternative donor types are comparable to those seen using HLA-matched siblings. Published by Elsevier Inc.

• 出版日期2015-7